Markets:

Overview

News

Currencies

International

Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.440 -0.050 (-3.36%)

Streaming Delayed Price Updated: 10:48 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ProQR Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >

Raymond James Bullish On This Penny Stock's Reprioritized Pipeline ↗

August 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022 ↗

August 12, 2022

Via Benzinga

This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing ↗

August 11, 2022

Via Benzinga

Expert Ratings for ProQR Therapeutics ↗

May 06, 2022

Within the last quarter, ProQR Therapeutics (NASDAQ:PRQR) has observed the following analyst ratings:

Via Benzinga

Where ProQR Therapeutics Stands With Analysts ↗

April 14, 2022

Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ:PRQR) within the last quarter:

Via Benzinga

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce ↗

April 13, 2022

Via Benzinga

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗

June 28, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 14, 2022

During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 29, 2022

On Friday, 213 companies hit new 52-week lows.

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Where ProQR Therapeutics Stands With Analysts ↗

February 14, 2022

Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ:PRQR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Mid-Afternoon Market Update: US Stocks Extend Losses; Dow Tumbles 450 Points ↗

February 11, 2022

US stocks extended losses toward the end of trading session, with the Dow Jones tumbling 450 points on Friday.

Via Benzinga

Mid-Day Market Update: Nasdaq Drops 100 Points; Bloom Energy Shares Jump ↗

February 11, 2022

The Nasdaq turned lower during the mid-day session, with the tech-laden index falling 100 points on Friday.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 16, 2022

On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗

February 14, 2022

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...

Via Benzinga

41 Stocks Moving In Friday's Mid-Day Session ↗

February 11, 2022

Gainers Modular Medical, Inc. (NASDAQ: MODD) shares climbed 34.5% to $4.99 following its recent uplisting to the Nasdaq Capital Market on Thursday. Kaival Brands Innovations...

Via Benzinga

78 Biggest Movers From Friday ↗

February 14, 2022

Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher As Dow Rises Over 100 Points ↗

February 11, 2022

U.S. stocks opened on a strong note on Friday, after recording sharp losses in the previous session.

Via Benzinga

52 Weeks High And Low Article ↗

February 11, 2022

On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company...

Via Benzinga

The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO ↗

February 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-...

Via Benzinga

ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder ↗

February 11, 2022

ProQR Therapeutics N.V. (NASDAQ: PRQR) shares are plunging after disappointing data from its pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 01, 2022

Rise and shine, trader! We're starting off another day of investing with a breakdown of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

16 Stocks Moving in Tuesday's Pre-Market Session ↗

February 01, 2022

Gainers ObsEva SA (NASDAQ: OBSV) rose 22.2% to $1.87 in pre-market trading after the company announced a corporate update, including an increase in share capital on...

Via Benzinga

The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings ↗

November 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

All News about ProQR Therapeutics N.V. - Ordinary Shares

Starting at $3.75/week.

Subscribe Today